Switch View
© Globe Newswire
10.11.2025
ISIN: US15117B1035
Celldex Therapeutics, Inc.
CLDX
LISTED
NASDAQ
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
News Preview
HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30 years of strategic, commercial launch and operating P&L leadership across the biopharmaceutical, medical de...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US92915B1061
Voyager Therapeutics Inc
VYGR
LISTED
NASDAQ
Voyager Reports Third Quarter 2025 Financial and Operating Results
News Preview
- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - ...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US92915B1061
Voyager Therapeutics Inc
VYGR
LISTED
NASDAQ
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
News Preview
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
10.11.2025
ISIN: DE000BAY0017
Bayer AG
BAYN
LISTED
XETR
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
News Preview
Today, on World Science Day, Bayer is proud to launch its “Science Delivers” campaign, a nationwide initiative celebrating how science delivers answers, hope, and progress for all Americans—every day, in the moments that matter most.
From the medicine that keeps us healthy to the technology that connects and helps feed us, to the innovations tha...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
10.11.2025
ISIN: US38942Q2021
CalciMedica Inc
CALC
LISTED
NASDAQ
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
News Preview
Treatment with Auxora significantly reduced IL-17–related inflammation in both kidney and lung, significantly increased glomerular filtration rate (GFR), and decreased renal injury in a rat model of AKI
Findings reinforce the mechanistic rationale for Auxora as a potential treatment for severe AKI with respiratory f...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ISIN: US04216R1023
Armata Pharmaceuticals, Inc.
ARMP
LISTED
XASE
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
News Preview
LOS ANGELES, Nov. 10, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US04272N1028
Arrivent Biopharma Inc
AVBP
LISTED
NASDAQ
ArriVent BioPharma Reports Third Quarter 2025 Financial Results
News Preview
NEWTOWN SQUARE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: “AVBP”), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30, 2025, and highlighted recent...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: CH0334081137
CRISPR Therapeutics AG
CRSP
LISTED
NASDAQ
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
News Preview
-Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine-...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US35104E1001
4D Molecular Therapeutics Inc
FDMT
LISTED
NASDAQ
4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
News Preview
EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q3 2025 financial results...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US5588681057
Madrigal Pharmaceuticals Inc
MDGL
LISTED
NASDAQ
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
News Preview
CONSHOHOCKEN, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced positive two-year data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US28659T2006
Elite Pharmaceuticals, Inc.
ELTP
LISTED
OTC
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
News Preview
Financials for Second Quarter of Fiscal Year 2026 Ended September 30, 2025 will be released on Friday, November 14, 2025Northvale, New Jersey--(Newsfile Corp. - November 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today th...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ISIN: JP3475350009
Daiichi Sankyo Co Ltd
45680
LISTED
XJPX
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
News Preview
The first patient has been dosed in a first-in-human phase 1 trial evaluating DS3610 in patients with advanced, metastatic or unresectable solid tumors.
DS3610 is an investigational STING agonist antibody drug conjugate (ADC) containing an immunomodulatory payload discovered by Daiichi Sankyo (TSE:4568).
Despite the availability of various can...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
10.11.2025
ISIN: US0373261058
AN2 Therapeutics Inc
ANTX
LISTED
NASDAQ
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
News Preview
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a collaboration agreement with the global biopharma company GSK to develop new therapies for tuberculosis (TB). As part of this effort, the Gates Foundation will provide a third year o...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ISIN: US30063P1057
Exact Sciences Corp
EXAS
LISTED
NASDAQ
Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome’s Blood-Based Colorectal Cancer Screening Tests
News Preview
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) for its previously announced license agreement with Freenome. Under the agreement, the Company acquired exclusive rights in the U...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ISIN: VGG111961055
Biohaven Ltd.
BHVN
LISTED
NYSE
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
News Preview
NEW HAVEN, Conn., Nov. 10, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financia...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
News Preview
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the company's first-in-cl...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US12674W1099
Cabaletta Bio Inc
CABA
LISTED
NASDAQ
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US86881A1007
Surgery Partners Inc
SGRY
LISTED
NASDAQ
Surgery Partners, Inc. Announces Third Quarter 2025 Results
News Preview
BRENTWOOD, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the third quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
News Preview
Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers ...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: SG9999014716
WAVE Life Sciences Ltd
WVE
LISTED
NASDAQ
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss and prevention of rebound weight gain following cessation of GLP-1 in preclinical models ...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US0554771032
Bicara Therapeutics Inc.
BCAX
LISTED
NASDAQ
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility
News Preview
Media Release...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US03770N1019
Apogee Therapeutics Inc
APGE
LISTED
NASDAQ
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
News Preview
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head readout against DUPIXENT in AD in 2H 2026...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
DXCM STOCK NOTICE: DexCom, Inc. Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 26 Deadline
News Preview
New York, New York--(Newsfile Corp. - November 10, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from the potential violations of th...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline
News Preview
New York, New York--(Newsfile Corp. - November 10, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
AVTR INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Avantor, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
News Preview
SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Avantor class action lawsuit – captioned Building Trades Pension Fund of Western Pennsylvania v. Avantor, Inc., No. 25-cv-06187 (E.D. Pa.) – seeks to represent purchasers or acquirers of Avantor, Inc. (NYSE: AVTR) com...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: NL0010696654
Uniqure NV
QURE
LISTED
NASDAQ
uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 months and supportive trends across key clinical and biomarker endpoints ~...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US00972D1054
Akebia Therapeutics Inc
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
News Preview
Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US28106W1036
Editas Medicine Inc
EDIT
LISTED
NASDAQ
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
News Preview
In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: BMG762791017
Roivant Sciences Ltd
ROIV
LISTED
NASDAQ
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
News Preview
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US15713L1098
CervoMed Inc.
CRVO
LISTED
NASDAQ
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
News Preview
Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB)...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US87990A1060
Tenaya Therapeutics Inc
TNYA
LISTED
NASDAQ
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US81734D1046
Septerna, Inc.
SEPN
LISTED
NASDAQ
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
News Preview
SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US68062P1066
Olema Pharmaceuticals, Inc.
OLMA
LISTED
NASDAQ
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
News Preview
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US9032141049
Cogent Biosciences, Inc.
COGT
LISTED
NASDAQ
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)
News Preview
16.5 months median progression free survival (mPFS) for bezuclastinib plus sunitinib compared to 9.2 months mPFS for sunitinib monotherapy (HR=0.50, CI: 0.39-0.65; p<0.0001)...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US67080M1036
Nurix Therapeutics Inc
NRIX
LISTED
NASDAQ
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
News Preview
Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertise Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertise...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: KYG596651029
MeiraGTx Holdings PLC
MGTX
LISTED
NASDAQ
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
News Preview
LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly and Company (“Lilly”)....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US03770N1019
Apogee Therapeutics Inc
APGE
LISTED
NASDAQ
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
News Preview
Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US82835W1080
ARS Pharmaceuticals Inc
SBTX
LISTED
NASDAQ
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
News Preview
$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ISIN: FR0014000MR3
Eurofins Scientific SE
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.11.2025
ISIN: CA50206C1005
LIR Life Sciences Corp.
SKNY
LISTED
CSE
Lir Life Sciences Corp. Formerly Blackbird Critical Metals Corp. Announces Closing of Acquisition of Lir Life Sciences Inc.
News Preview
VANCOUVER, BC / ACCESS Newswire / November 10, 2025 / Lir Life Sciences Corp. (CSE:SKNY) (formerly Blackbird Critical Metals Corp.) ("Lir Life Sciences" or the "Company") is pleased to announce, further to its news release dated August 14, 2025, that it has completed the acquisition (the "Transaction") of all of the is...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
News Preview
REYKJAVIK, ICELAND (November 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) a...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
News Preview
REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ISIN: NL0015002CX3
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
News Preview
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting from November 11-15 in Boston.
The first public introduction of QIAsymphony Con...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ISIN: FR0010331421
Innate Pharma SA
IPH
LISTED
EURONEXT
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
News Preview
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL), with no further comments, clearing the trial to proceed.
The planned...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: FR0004163111
Genfit SA
GNFT
LISTED
EURONEXT
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces a research collaboration with EVerZom to expand its Acute-On-Chronic Lier Fail...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: FR0004163111
Genfit SA
GNFT
LISTED
EURONEXT
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today presents promising new preclinical data in ACLF at The Liver Meeting® 2025 with nitazoxa...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
News Preview
Basel, 10 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the first Phase III (FENhance 2) of two pivotal, similarly-designed Phase III studies (FENhance 1 and 2) in patients with relapsing multiple sclerosis (RMS) met its primary endpoint. Fenebrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, significan...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCM
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline.SO WHAT: If you purchased...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LANTHEUS DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action - LNTH
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the important November 10, 2025 lead plaintiff deadline.SO WHAT: If y...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Molina Healthcare, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOH
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), of the important December 2, 2025 lead plaintiff deadline.SO WHAT: If you pur...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BAX
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WHAT:...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
ROSEN, A TOP RANKED LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.SO WHAT: If you...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
ROSEN, A TOP RANKED LAW FIRM, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Avantor, Inc. (NYSE: AVTR) between March 5, 2024 and October 28, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has alrea...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ISIN: KYG4818G1010
Innovent Biologics Inc
1801
LISTED
HKSE
Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
News Preview
IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration.
The clinical Phase 1 data of IBI3016 further support the potential for biannual subcutaneous dosing for the treatment of hypertensi...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 9, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (N...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ISIN: US92764N1028
Vir Biotechnology Inc
VIR
LISTED
NASDAQ
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants receiving a monthly dose of the combination of tobevibart and elebsiran achieved robust and sustained rates of hepatitis delta virus (HDV) RNA target not det...
Themefolio
Profiler
Peergroup
© BusinessWire
09.11.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial demonstrating that treatment with enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in a statistic...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.11.2025
ISIN: AU000000AVH4
Avita Medical Inc.
AVH
LISTED
ASX
AVITA Medical to Host Investor Webinar Briefing
News Preview
AVITA Medical to Host Investor Webinar Briefing...
Themefolio
Profiler
Peergroup
© BusinessWire
09.11.2025
ISIN: US28176E1082
Edwards Lifesciences Corp.
EW
LISTED
NYSE
Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease
News Preview
Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association’s Heart Valve Initiative, a national effort to improve care and outcomes for the more than 28 million people living with heart valve disease worldwide. In the U.S. alone, valve disease contributes to more than 60,000 deaths annually, many dri...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
